BIONEER
Innovation • Value • Discovery

# Investor Relations Brief

10

2024

October


※ 바이오니아는 투자 판단에 참고할 만한 정보를 제공할 뿐이며 투자에 대한 책임은 투자자에게 있음을 알려드립니다.

# Business Division Progress Report

## Molecular Diagnostics

BIONEER has become the first in Asia to obtain WHO PQ certification for its HIV-1 quantitative diagnostic kit, securing the qualification to participate in procurement bids conducted by WHO and other international organizations. As the first company in Asia to pass the stringent certification in the highly technical field of HIV diagnostic kits, it is expected that trust in the company's proprietary technology will significantly increase across the industry. Building on this, the company aims to strengthen its position in the global market, including low- and middle-income countries, and achieve more than 30% market share for WHO PQ-certified products within the next three years.

## CosmeRNA

From September 12 to 14, BIONEER introduced CosmeRNA to global medical professionals and specialized distributors at the Barcelona Hair Meeting. Following this, we set up an exclusive booth at EADV 2024, held in Amsterdam from September 25 to 28, where we actively promoted our recently launched B2B product, CosmeRNA Intensive. The product garnered significant attention from experts, reaffirming the innovation and strong market potential of our offerings. In particular, the event facilitated close collaboration opportunities with medical professionals from various regions, including Europe, the United States, and India, which is expected to serve as an important step toward accelerating the global expansion of CosmeRNA.

Meanwhile, in countries where contracts and regulatory approvals have been completed, preparations for the official launch are well underway, ensuring all necessary arrangements for a successful market entry.

## AceBiome

Anaparectin was selected as the Winner in the Sports Nutrition category at the NutraIngredients-Asia Awards 2024, held in Bangkok, Thailand. In a market with few sports nutrition products targeting the growing middle-aged and baby boomer generations, the product received high praise for its clear focus on the senior demographic. Winning this prestigious award, which recognizes the excellence of global functional ingredients and products, has further strengthened our position not only in the domestic market but also globally.

Meanwhile, we have also launched Etnacare, an ingestible skin supplement featuring ROCH (Red Orange Complex H) as its main ingredient, a functional raw material recognized by the Ministry of Food and Drug Safety for maintaining skin health from UV damage and enhancing skin moisture.

## siRNAgen

SiRNAgen Therapeutics has received the final report for the Phase 1a clinical trial of its next-generation drug candidate, SRN-001. The trial confirmed that drug exposure increased proportionally with the dose when administered intravenously, and no cytokine changes or anti-SRN-001 antibodies were observed. Cytokine-related immunogenicity issues are known to be one of the major challenges in ensuring the safety of siRNA therapies. Additionally, no significant changes were observed before and after administration in all safety evaluation parameters, including ECG results, demonstrating that the drug is safe even at the highest dose.

# Bioneer News

## EADV 2024

BIONEER successfully concluded its participation at the 2024 EADV, held from September 25 to 28 in Amsterdam, where it showcased the innovative hair loss cosmetic CosmeRNA and the IRON-qPCR™ hair loss mRNA test..


BIONEER unveiled its clinic-exclusive product, CosmeRNA Intensive(1㎖ x 10ea), for the first time at this exhibition, officially launching promotions and accepting order requests. Many dermatologists and distributors at the event showed great interest in the clinic-exclusive product, which is expected to further energize the company's B2B business moving forward.


▲ CosmeRNA Intensive / CosmeRNA 6㎖/ CosmeRNA 2㎖

Additionally, a demonstration was conducted using the on-site molecular diagnostic device, IRON-qPCR™, to test mRNA levels related to hair loss. The industry evaluated that the device has the potential to become the standard for future hair loss molecular diagnostics, as it can quantitatively analyze results within 40 minutes.






▲ BIONEER’s EADV 2024 Brochure

# Bioneer News







CosmeRNA, which aids in hair loss management by lowering the mRNA level of androgen receptors, one of the hair loss-inducing mRNAs within hair follicles, has been recognized for its innovation in the global market. It won the Hair Product of the Year award in the Hair Care category at Cosmoprof Awards 2024, the world's largest cosmetics exhibition, with 400,000 participants.

Through follow-up meetings with connected partners, the company plans to further expand CosmeRNA's overseas sales channels and enhance its global competitiveness through participation in various international conferences. Simultaneously, the company aims to expand its business by linking CosmeRNA with customized clinic services using the IRON-qPCR™ hair loss diagnostic solution, creating a new paradigm for personalized hair loss management in collaboration with global hair loss and dermatology experts.

# Bioneer News

## Participation in Academic Events

BIONEER participated in various domestic conferences and exhibitions, promoting its next-generation diagnostic products, including the IRON-qPCR™, which is optimized for syndromic diagnostics and can detect up to 40 targets within 40 minutes, to local specialists and pathologists.

### 2024 KAMT(The Korean Association of Medical Technologists) 8/30~31





### 2024 KSCBRD(Korean Society of Chemical, Biological, Radiological, and Nuclear Defense) 9/10~11


# Bioneer News

## 2024 LMCE (Laboratory Medicine Congress & Exhibition) 9/25~28

The LMCE, hosted by the Korean Society for Laboratory Medicine, is a key event where professionals in pathology and laboratory medicine gather to discuss the latest advancements in technology. At this event, BIONEER presented the analytical and clinical performance of its ExiSation FA 96/384 and HIV-1, HBV, HCV Viral Load Kits, showcasing impressive results. Additionally, the company introduced the performance evaluations of IRON-qPCR and RFIA (MTB, MDR, XDR, CRE Kits). Notably, BIONEER promoted its recently WHO PQ-certified HIV-1 Kit at the exhibition booth, attracting considerable interest and inquiries, particularly from attendees from Africa and Southeast Asia, regions with high local demand.






# Bioneer News

## SRN-001 Phase 1a Clinical Results Summary

### Summary of Adverse Drug Reactions

Among the 17 participants in the drug administration group and 8 in the placebo group, no adverse reactions that required dose escalation to be halted or the study to be discontinued were observed in the 17 participants receiving the investigational drug during the study period. Additionally, only general symptoms were observed in all participants due to either the placebo or SRN-001, with no clinically significant abnormal responses in laboratory tests or ECG results. The incidence of adverse reactions in the SRN-001 group was similar to that in the placebo group, and no signs of increased adverse reactions with dose escalation were detected.

| Adverse Reactions | Cohort 1 (n=4) | Cohort 2 (n=4) | Cohort 3 (n=5*) | Cohort 4 (n=4) | Placebo (saline, n=8) |
|---|---|---|---|---|---|
| Adverse reactions following drug administration(Number of subjects with symptoms / number of occurrences) | 2/10 | 2/2 | 3/15 | 2/5 | 7/18 |
| Adverse reactions related to the drug(Number of subjects with symptoms / number of occurrences) | 1/1[1)] | 0 | 2/9[2)] | 1/3[3)] | 1/6[4)] |
| Cases of discontinuation due to adverse reactions | 0 | 0 | 0 | 0 | 0 |
| Serious adverse reactions | 0 | 0 | 1[5)] | 0 | 0 |
| Serious adverse reactions related to the drug | 0 | 0 | 0 | 0 | 0 |
| Frequency of adverse reactions after drug administration (subjects) | 2(50%) | 2(50%) | 3(60%) | 2(50%) | 7(87.5%) |

* Cohort 3 : Due to technical issues with the drug equipment, an additional participant was recruited and administered the drug.

1) Headache
2) Injection site pain/redness, paresthesia, itching, and productive cough with sputum
3) Chest discomfort, palpitations
4) Injection site pain, redness at the blood draw site, diarrhea, nausea, abdominal pain, and vomiting
5) Grade 3 back pain, The symptoms resolved without any treatment or medication, confirming that they were unrelated to the drug

### Summary of Biomarker

No significant changes in cytokine levels related to the innate immune response were observed in any of the participants who received SRN-001.

| Biomarker | Cohort 1 (n=4) | Cohort 2 (n=4) | Cohort 3 (n=5) | Cohort 4 (n=4) | Placebo (n=8) |
|---|---|---|---|---|---|
| CH50 | 2.40 (+/-23.9) | -10.8 (+/-33.9) | 9.92 (+/-44.6) | 12.5 (+/-19.3) | 10.8 (+/-18.5) |
| Interferon Gamma | 0.136 (N/A) | 0.215 (+/-0.619) | 0.106 (+/-1.29) | -1.38 (+/-1.07) | -0.312 (+/-1.29) |
| Interleukin 6 | 1.23 (+/-1.31) | 2.68 (+/-2.90) | 2.12 (+/-2.09) | 1.91 (+/-1.20) | 2.83(+/-3.09) |
| Interleukin 1 beta, TNF | BLLOQ | BLLOQ | BLLOQ | BLLOQ | BLLOQ |

- CH50 level: A measure indicating the activity of the immune system.
- Interferon Gamma, Interleukin 6, Interleukin 1 beta, TNF : Factors that regulate inflammatory responses
- BLLOQ : Below the Limit of Qualification